MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329 

October 28-30, 2020

Final - October 27, 2020

PRESIDER/PRESENTER(s)

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

10:30 Immunization Schedules

Introduction to combined immunization schedule work group	

Proposed changes to 2021 child/adolescent immunization 

schedule	

Proposed changes to 2021 adult immunization schedule

Dr. Hank Bernstein (ACIP, WG Co-Chair) 

Dr. Kevin Ault (ACIP, WG Co-Chair)

Dr. Patricia Wodi (CDC/NCIRD)

Dr. Mark Freedman (CDC/NCIRD)

11:30

11:45 Seasonal Influenza Vaccines 

Introduction 

Efficacy of cell-derived quadrivalent influenza vaccine (Flucelvax 

Quadrivalent) in children & adolescents ≥2 years to <18 years old

Influenza Disease Burden and Vaccine Impact Estimates, 2019-20 

Season

End-of-Season Estimates of 2019–20 Seasonal Influenza Vaccine 

Effectiveness against Medically Attended Influenza from three 

U.S. Networks

Updates and WG Considerations

Dr. Keipp Talbot (ACIP, WG Chair)

Dr. Gregg Sylvester (Seqirus)

Dr. Carrie Reed (CDC/NCIRD)

Dr. Lisa Grohskopf (CDC/NCIRD)

Dr. Lisa Grohskopf (CDC/NCIRD)

12:30

1:15 Orthopoxvirus Vaccine

Introduction

Orthopoxvirus work group background

JYNNEOS® (MVA-BN®) Smallpox and Monkeypox Vaccine 

Variola virus plaque reduction neutralization assay for the 

Vaccinating against monkeypox in the Democratic Republic of the

Congo with JYNNEOS®

Next Steps 

Dr. Beth Bell (ACIP, WG Chair)

Dr. Brett Petersen (CDC/NCEZID)

Dr. Heinz Weidenthaler (Bavarian Nordic)

Dr. Christina Hutson (CDC/NCEZID) 

Dr. Brett Petersen (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID) 

2:45

2:55 Dengue Vaccines

Introduction Dr. Robert Atmar (ACIP, WG Chair) 

3:05 Pneumococcal Vaccines 

Work group introduction Dr. Katherine Poehling (ACIP, WG Chair) 

Dr. Miwako Kobayashi (CDC/NCIRD)

3:15 Cholera Vaccines 

Work group introduction Dr. Pablo Sanchez (ACIP, WG Chair)

3:25

3:30

4:15

4:20 Dr. Mark Freedman (CDC/NCIRD)

4:30 Adjourn

Public Comment

Break

Vote - Immunization Schedules

Lunch

Break

AGENDA ITEM

Wednesday, October 28, 2020

10:00 Welcome & Introductions

Break

Break

page 1 of 3
10:15 Zoster Vaccine 

Introduction

Update on post-licensure safety monitoring of recombinant 

zoster vaccine (RZV, Shingrix) in the Vaccine Adverse Event 

Reporting System (VAERS)

Vaccine Safety Datalink (VSD) update on post-licensure safety 

monitoring of RZV

Risk of Guillain-Barré syndrome following herpes zoster 

Summary and planned risk-benefit analysis regarding use of RZV

in immunocompetent adults

Planned risk-benefit analysis regarding use of RZV in 

immunocompetent adults

Dr. Grace Lee (ACIP, WG Chair)

Dr. John Su (CDC/NCEZID)

Dr. Jennifer Nelson (Kaiser Permanente)

Dr. Tara Anderson (CDC/NCIRD)

 Dr. Tara Anderson (CDC/NCIRD)

Dr. Tara Anderson (CDC/NCIRD)

11:45

12:20 Tick-borne Encephalitis Vaccine 

Introduction

Overview of tick-borne encephalitis (TBE) and TBE vaccine

Immunogenicity and safety of Pfizer's TBE vaccine

Next steps for TBE vaccine work group

Dr. Katherine Poehling (ACIP, WG Chair)

Dr. Susan Hills (CDC/NCEZID)

Dr. Dr Heinz-Joseph Schmitt (Pfizer)

Dr. Susan Hills (CDC/NCEZID)

2:00

2:15 Rabies Vaccine

Introduction

Minimum acceptable rabies antibody titer and implications on 

ACIP recommendations

Pertinent fundamentals of rabies immunology

Dr. Sharon Frey (ACIP, WG Chair)

Dr. Susan Moore (Kansas State University)

Dr. Deborah Briggs (Kansas State University)

3:30

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

4:50 Adjourn

Pre-exposure prophylaxis schedule: Grading of recommendations 

assessment, development, and evaluation (GRADE)

Evidence to recommendation framework (EtR)

Summary and next steps

Break

Lunch

Thursday, October 29, 2020

10:00 Unfinished Business and Agency Updates

CDC, CMS, FDA, HRSA, IHS, NIH, OIDP

Break

Final - October 27, 2020

page 2 of 3
10:00 Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction

Update from Vaccines and Related Biological Products Advisory 

Committee (VRBPAC) meeting

NVX-CoV2373 Vaccine Candidate

Janssen's SARS-CoV-2 Vaccine Program

Dr. Beth Bell (ACIP, WG Chair)

Dr. Doran Fink (FDA)

Dr. Filip Dubovsky (Novavax)

Dr. Jerry Sadoff (Janssen)

11:45

12:00 Update on vaccine implementation planning

Vaccinate with Confidence

Dr. Janell Routh (CDC/NCIRD)

Dr. Amanda Cohn (CDC/NCIRD)

12:30

1:15 FDA safety surveillance systems

Post-authorization safety monitoring plans

Modeling strategies for the initial allocation of COVID-19 vaccines

Dr. Steven Anderson (FDA)

Dr. Tom Shimabukuro (CDC/NCEZID)

Dr. Matthew Biggerstaff (CDC/NCIRD)

2:30

2:45 Updates to immunity and epidemiology to inform COVID-19 

Ethical principles for early vaccine allocation 

Work Group interpretation of data

Policy questions, Evidence to Recommendation Framework, and 

Discussion 

Dr. Megan Wallace (CDC/NCIRD)

Dr. Mary Chamberland (CDC/NCIRD)

Dr. Sara Oliver (CDC/NCIRD)

Dr. Kathleen Dooling (CDC/NCIRD)

4:45 Adjourn

Acronyms

CDC

CMS

COVID-19

EtR

FDA

GRADE

HRSA

IHS

NCHHSTP

NCIRD

NCEZID

NIAID

OIDP

RZV

SAGE

SARS-CoV-2

WG

WHO

VAERS

VE

Lunch

Vaccine Effectiveness

Strategic Advisory Group of Experts

Office of Infectious Disease and HIV/AIDS Policy

Severe Acute Respiratory Syndrome coronavirus 2

Indian Health Service

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

Work Group

National Institute of Allergy and Infectious Diseases

Recombinant Zoster Vaccine

World Health Organization

Discussion 

Friday, October 30, 2020

Vaccine Adverse Event Reporting System

Health Resources and Services Administration

Coronavirus Disease 2019

Centers for Medicare and Medicaid Services 

Centers for Disease Control and Prevention

Food and Drug Administration

Grading of Recommendations Assessment, Development and Evaluation

Evidence to Recommendations Framework

Break

Break

Final - October 27, 2020

page 3 of 3